Alembic Pharma gets USFDA EIR for Karakhadi facility
Gujarat: Drugmaker, Alembic Pharma, has announced that the company has received Establishment Inspection Report (EIR) from US Food and Drug Administration (USFDA) for the inspection carried out at its New Injectable Facility (F-3) at Karakhadi, Gujarat.
The inspection was conducted from 28th January, 2021 to 5th February, 2021.
USFDA has also indicated that a compliance verification would be performed during re-inspection of the said facility in the next review cycle.
In February, Alembic Pharma had got five observations from US health regulator after inspection at its facility at Karkhadi, Gujarat.
Read also: Alembic Pharma Gujarat Facility Gets 5 USFDA Observations
Alembic Pharmaceuticals Limited is a vertically integrated research and development pharmaceutical company headquartered in Gujarat.
Read also: Alembic Pharma bags USFDA nod for Clomipramine Hydrochloride Capsules to treat OCD
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.